Text size :

Rare diseases, Torraca (Apacs): “Early diagnosis of EGPA cannot depend on the right doctor”

ADNKRONOS

November 13, 2026

Rome, Nov 13. (Adnkronos Health) – “Often the first symptoms of EGPA, such as asthma, chronic rhinosinusitis, and nasal polyposis, appear many years before the disease is recognized and are addressed separately by different specialists. The result is that years can pass for patients before reaching a correct diagnosis. Early diagnosis cannot depend solely on the luck of meeting the right doctor.” So says Francesca Torraca, president of Apacs, on the sidelines of the Congress of the Italian Society of Internal Medicine (Simi) Emilia Romagna and Marche section, currently underway in Ancona, speaking about eosinophilic granulomatosis with polyangiitis, a rare vasculitis that can cause even irreversible organ damage if not recognized promptly.

“For a systemic disease like EGPA, multidisciplinarity is not an added value but a clinical necessity – emphasizes Torraca – The pathology can simultaneously involve different organs and systems and requires the contribution of multiple specialists. Multidisciplinarity primarily means networking, sharing clinical information, and defining a common therapeutic strategy,” remarks the president of Apacs, Churg Strauss – EGPA Aps Patients’ Association, highlighting that too often the patient finds themselves having to independently coordinate visits, exams, and different therapeutic indications. “It is a responsibility that should not fall on those already living with a chronic and complex pathology. A doctor who acts as a director is needed – she clarifies – and a multidisciplinary team capable of ensuring continuous and coordinated care.”

Among the priorities identified by the patient association are: the definition of specific and homogeneous diagnostic-therapeutic-assistance pathways (Pdta) nationwide; the strengthening of networks between specialized centers and territorial medicine, and more uniform access to innovative therapies. “Not all patients today have the same care opportunities, and this represents a significant critical issue,” reiterates Torraca. On the therapeutic front, “the introduction of biological therapies has significantly changed the prospects of many patients – observes the Apacs president – offering new possibilities for disease control and reducing prolonged exposure to corticosteroids” and long-term side effects. However, “innovation has concrete value only if it is truly accessible and if it promptly reaches all patients who need it,” without territorial disparities. “We cannot think that all EGPA patients should move to a few centers of excellence to receive adequate care – she concludes – We must build a network where the expertise of the most specialized centers can be shared and made available to peripheral structures as well.”

Jiji Press

Related

Page TOP